Zydus Life Science

ZYDUSLIFE

NSE

BSE

SectorHealthcare

Loading chart…

Company insights, generated from the most recent coverage.

Stock trades at 18.77x PE vs industry median 31.79x, and EV/EBITDA 12.59x vs 17.09x — valuation discount reflects near-term margin pain but offers upside if specialty transition succeeds.
Read more
Market reaction shows sophisticated investor patience: willingness to accept quarterly profit volatility for long-term strategic transformation from generics to high-margin specialty therapies.
Read more
Pipeline catalysts include Saroglitazar US NDA filing (Q4 FY26), 14-15 critical launches in FY27, and Semaglutide international expansion — potential re-rating triggers if commercialization succeeds.
Read more

The Quarter story

The two most recent quarterly results, compared side-by-side.

Revenue crosses ₹80,000 Cr in Q1 FY27 driven by dominant consumer brands, while margin compression and currency headwinds pressure profitability.

Consolidated revenue grew from ₹65,737 Cr to ₹80,170 Cr from Q1 FY26 to Q1 FY27, confirming strong top-line momentum

EBITDA margin fell from 33.7% to 24.1% from Q4 FY26 to Q1 FY27, showing profit compression

Gross margin improved from 72.8% to 74.0% from Q1 FY26 to Q4 FY26, reflecting robust cost management

North America sales share dropped from 49% to 10% from Q1 FY26 to Q1 FY27, signaling a major portfolio mix shift

Glucon-D and Sugar Free held market rank 1 from Q1 FY26 through Q1 FY27, maintaining unchallenged category leadership

Net debt climbed from -₹56,312 Cr to ₹43,050 Cr from Q1 FY26 to Q4 FY26, indicating rising leverage

R&D spending rose from ₹4,856 Cr to ₹6,982 Cr from Q1 FY26 to Q4 FY26, accelerating innovation pipeline execution

Net forex losses widened from -₹571 Cr to -₹6,449 Cr from Q1 FY26 to Q4 FY26, highlighting persistent currency headwinds

North America regulatory approvals increased from 6 to 9 from Q1 FY26 to Q4 FY26, expanding US market access

Other operating expenses rose from ₹13,648 Cr to ₹18,732 Cr from Q1 FY26 to Q4 FY26, pressuring bottom-line efficiency

About the company

Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.

In the news